Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

D-085

Supelco

Dexamethasone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H29FO5
Numéro CAS:
Poids moléculaire :
392.46
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

Clé InChI

UREBDLICKHMUKA-CXSFZGCWSA-N

Informations sur le gène

human ... NR3C1(2908)

Description générale

Dexamethasone is a potent glucocorticoid which acts as an anti-inflammatory and immunosuppressant for therapeutic treatments in many inflammatory and autoimmune conditions, oncology, and endocrine diseases such as Addison′s disease. Dexamethasone levels in serum or plasma are measured by LC-MS/MS for dexamethsaone suppression tests or monitoring dexamethsaone treatment regimens. This Certified Spiking Solution® is suitable for use as starting materials in the preparation of calibrators and controls for dexamethasone testing methods by LC-MS/MS.

Application

  • Controlled drug delivery systems: Hydrogel microneedles incorporating dexamethasone demonstrate a programmed mesophase transition, optimizing the controlled release of drugs for therapeutic applications. This advancement in drug delivery technology illustrates the utility of dexamethasone solution in developing innovative pharmaceutical materials (Dawud et al., 2024).
  • Enhanced nasal drug administration: Bovine Serum Albumin nanoparticles, integrated with dexamethasone, highlight a novel gelling system designed to enhance nasal drug delivery. This research underscores the potential of dexamethasone solution in creating more effective and patient-friendly drug delivery modalities (Mardikasari et al., 2023).
  • Sustained-release formulations: The development of polyvinyl alcohol microparticles for the sustained release of dexamethasone via a coaxial microfluidic system demonstrates the critical role of dexamethasone solution in producing precision drug delivery systems that improve therapeutic efficacy and patient compliance (Abdi Majareh et al., 2023).
  • Topical drug delivery for ocular conditions: Dexamethasone-loaded chitosan nanoparticles were developed for topical application in a rabbit model of endotoxin-induced uveitis, indicating significant advancements in localized drug delivery systems using dexamethasone solutions. This application is particularly relevant in treating inflammatory eye diseases with enhanced drug delivery efficiency (Alkholief et al., 2023).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

FlameSkull and crossbonesHealth hazard

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

María-Victoria Mateos et al.
The New England journal of medicine, 369(5), 438-447 (2013-08-02)
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. In this randomized, open-label, phase 3 trial, we randomly assigned 119
Shankar Swaminathan et al.
Journal of biomedical nanotechnology, 9(6), 998-1007 (2013-07-19)
Nanosponges (NS) were synthesized by crosslinking of beta cyclodextrins with diphenyl carbonate. It is a hyper-branched polymer with an ultra high encapsulation efficiency leading to formation of colloidal systems. Dexamethasone (DEX) on the other hand is a poorly soluble drug
Fausto Roila et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(2), 101-106 (2013-12-11)
A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer. The aim of this study was to verify
Erich Piovan et al.
Cancer cell, 24(6), 766-776 (2013-12-03)
Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically
Peter Bärtsch et al.
The New England journal of medicine, 368(24), 2294-2302 (2013-06-14)
A 45-year-old healthy man wishes to climb Mount Kilimanjaro (5895 m) in a 5-day period, starting at 1800 m. The results of a recent exercise stress test were normal; he runs 10 km 4 or 5 times per week and

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique